Bad news for Zepto as Maharashtra FDA cancels license of.., due to...
In fresh trouble for Zepto, the Maharashtra Food and Drug Administration (FDA) has launched a crackdown on its operations across Mumbai, and cancelled the license of its Dharavi facility for non-compliance with food standards. As per the FDA, Zepto's Dharavi facility was shuttered for violating several regulations, including Food Safety and Standards Act, 2006 and the Food Safety and Standards (Licensing and Registration of Food Businesses) Regulations, 2011, according to a report by NDTV Profit. Maharashtra FDA cracks down on Zepto
The state FDA had also found norms violations during inspections at Zepto facilities in Bhiwandi, Bandra West and Borivali. The authority sent notices to the Bhiwandi and Bandra East facilities, and suspended the food business license of the Borivali location, due to which the quick commerce firm was prompted to implement corrective measures and was allowed to restart operations, report said, quoting an FDA official. Gross violations found at Zepto's Dharavi facility
According to the agency, gross violations of food standards norms were found at Zepto's Dharavi facility, including fungal growth in certain food articles, and food products stores near stagnant water, which indicated poor hygiene as cold storage rules were flouted. The inspection also discovered the facility's floors were wet and filthy, and food items were stored in a disorganized and unsanitary manner, including directly on the floor.
The agency also found that expired products were mixed with non-expired stock. Zepto's Dharavi license suspended
As per the NDTV report, the agency conducted the inspection based on on information received from Minister of State for FDA Yogesh Kadam, and cancelled the facility's license after its findings discovered norms violations. Additionally, Assistant Commissioner (Food), Anupamaa Balasaheb Patil, has ordered an immediate suspension under Section 32(3) of the Food Safety and Standards Act, 2006 and Regulation 2.1.8(4) of the Licensing and Registration Regulations, 2011.
As per the order, the suspension would remain in effect until Zepto achieves full compliance and receives approval from the licensing authority, the report said.
Responding to the development, a Zepto spokesperson asserted the quick commerce company is dedicated to ' maintaining the highest standards of food safety and hygiene', and added that the firm has initiated an internal review, and is working closely with concerned agencies 'to ensure full and swift compliance.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 hours ago
- Economic Times
Reliance Infrastructure, Reliance Power shares fall up to 5%. Here's why
Shares of Anil Ambani-led companies fell up to 5% on Thursday amid an ongoing investigation into a suspected Rs 17,000 crore loan fraud. ADVERTISEMENT Reliance Infrastructure declined 4% to a day's low of Rs 282, while Reliance Power dropped 5% to Rs 45.25 on the BSE. This comes a day after both stocks surged 5% on Wednesday. Over the past two weeks, Reliance Infrastructure shares have fallen 20%, while Reliance Power has declined 23%. The Enforcement Directorate (ED) questioned Reliance Group chairman Anil Ambani on Tuesday in connection with its money laundering probe into an alleged Rs 17,000 crore bank loan fraud has sought seven days to furnish documents pertaining to the queries posed to him by the ED, according to a report by ET ED will question another close aide, Sateesh Seth of Reliance Group on Thursday and on Wednesday, it questioned Amitabh Jhunjhunwala, a former close aide of Ambani. ADVERTISEMENT Loans to group firms—Reliance Home Finance Ltd, Reliance Commercial Finance Ltd, and Reliance Communications—amounting to around Rs 17,000 crore have reportedly turned into non-performing assets (NPAs), involving nearly 20 lenders. Nearly 20 private and public sector banks had given loans to Anil Ambani's entities over a period of time, which eventually turned into non-performing assets. Three entities of Reliance Group - Reliance Home Finance Limited (RHFL), Reliance Commercial Finance Ltd. (RCFL) and Reliance Communications (RCom) - were given a total of about ₹17,000 crore by the banks. ADVERTISEMENT According to data available with the ED, RHFL has an outstanding loan of more than ₹5,901 crore, while the amount in the case of RCFL is about ₹8,226 crore and RCom owes nearly Rs 4,105 crore. Besides YES Bank, the other banks that had given loans to Reliance Group include State Bank of India, UCO Bank, Axis Bank, ICICI Bank, HDFC Bank, Bank of India and Punjab and Sind Bank, the ETBureau report said. ADVERTISEMENT According to SEBI, evidence collected during the investigation indicates that CLE was functionally a related party of R Infra. Documentation cited by the regulator included submissions by CLE to Yes Bank, where it acknowledged Reliance Infra as a promoter. Internal records, such as audit committee meeting minutes, reportedly identified CLE as a 'group company.'On Wednesday, Reliance Infrastructure replied to clarification sought by NSE on increase in volume. The company said that the company is compliant with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and has been promptly informing the Stock Exchanges of all events and information impacting Company's operations or performance. Secondly, the company cannot comment on the volume of its securities on the exchanges. The company will continue to make appropriate disclosures, in accordance with applicable regulations, as and when any disclosable event occurs. (You can now subscribe to our ETMarkets WhatsApp channel)
Business Standard
4 hours ago
- Business Standard
Intas Pharmaceuticals and Accord BioPharma Become One of the Largest Global Suppliers of Pegfilgrastim with Acquisition of UDENYCA®
PRNewswire Ahmedabad (Gujarat) [India], August 7: Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified its position as one of the world's leading suppliers of pegfilgrastim following the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences, Inc. UDENYCA®, a biosimilar to Neulasta® (pegfilgrastim), significantly expands Intas and Accord's FDA-approved biosimilar portfolio and accelerates their strategic growth in the global biosimilar market. Accord is already a pegfilgrastim market leader in Europe--having been the first to commercialize a biosimilar pegfilgrastim and the only company to launch an autoinjector-- has maintained its leadership despite intense competition. This acquisition further strengthens the company's presence and impact in both the U.S. and international biosimilar landscapes. With the acquisition, Accord BioPharma, the U.S. specialty business of Intas, continues the commercialization of UDENYCA® to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. UDENYCA® offers three patient-friendly administration options--autoinjector (AI), on-body injector (OBI), and prefilled syringe (PFS)--providing flexibility for treatment at home, on-the-go, or in clinical settings. Since its commercial launch, over 300,000 patients have been treated with UDENYCA® and more than 1.4 million units have been distributed. The acquisition not only expands Accord BioPharma's product offerings but also brings a wealth of talent from Coherus BioSciences. Key Coherus employees across multiple functions, including Sales, Marketing, Finance, Supply Chain, and Quality and Manufacturing, who have joined Accord BioPharma, will play a crucial role in supply and services continuity/transition and expanding the company's work around UDENYCA®. Paul Tredwell, EMENA Executive Vice-President of Accord, added: "With the Accord Biopharma team now fully commercializing UDENYCA® in three different formulations, this development strengthens Accord's offering and advances our goal of becoming the world's leading supplier of pegfilgrastim." UDENYCA® (pegfilgrastim-cbqv) INDICATION UDENYCA® is a leukocyte growth factor indicated to: * Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. * Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). Limitations of Use UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. IMPORTANT SAFETY INFORMATION CONTRAINDICATION: Patients with a history of serious allergic reactions to pegfilgrastim products or filgrastim products. Reactions have included anaphylaxis. WARNINGS AND PRECAUTIONS: - Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture. - Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS. - Serious allergic reactions, including anaphylaxis: The majority of reported events occurred upon initial exposure. Allergic reactions, including anaphylaxis, can recur within days after the discontinuation of initial anti-allergic treatment. Permanently discontinue UDENYCA® in patients with serious allergic reactions. - Allergies to Acrylics (UDENYCA ONBODY® only): The on-body injector (OBI) for UDENYCA® uses acrylic adhesive. For patients who have reactions to acrylic adhesives, use of this product may result in a significant reaction. - Sickle cell crises: Severe and sometimes fatal crises have occurred. Discontinue UDENYCA® if sickle cell crisis occurs. - Glomerulonephritis: The diagnoses were based upon azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events resolved after dose reduction or discontinuation. Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely. - Leukocytosis: White blood cell (WBC) counts of 100 x 109/L or greater have been observed in patients receiving pegfilgrastim products. Monitoring of complete blood count (CBC) during UDENYCA® therapy is recommended. - Thrombocytopenia: Thrombocytopenia has been reported in patients receiving pegfilgrastim. Monitor platelet counts. - Capillary Leak Syndrome: Has been reported after G-CSF administration, including pegfilgrastim products, and is characterized by hypotension, hypoalbuminemia, edema, and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. If symptoms develop, closely monitor and give standard symptomatic treatment, which may include a need for intensive care. - Potential for Tumor Growth Stimulatory Effects on Malignant Cells: The granulocyte colony stimulating factor (G-CSF) receptor through which pegfilgrastim products and filgrastim products act has been found on tumor cell lines. The possibility that pegfilgrastim products act as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which pegfilgrastim products are not approved, cannot be excluded. - Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) in Patients with Breast and Lung Cancer: MDS and AML have been associated with the use of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy in patients with breast and lung cancer. Monitor patients for signs and symptoms of MDS/AML in these settings. - Potential Device failures ( UDENYCA ONBODY® only): Missed or partial doses have been reported for products administered via on-body injectors due to the device not performing as intended. In the event of a missed or partial dose, patients may be at increased risk of events such as neutropenia, febrile neutropenia and/or infection than if the dose had been correctly delivered. Instruct patients using the OBI to notify their healthcare professional immediately to determine the need for a replacement dose of UDENYCA® if they suspect that the device may not have performed as intended. - Aortitis: Has been reported in patients receiving pegfilgrastim products, occurring as early as the first week after start of therapy. Manifestations may include generalized signs and symptoms such as fever, abdominal pain, malaise, back pain, and increased inflammatory markers (e.g., c-reactive protein and white blood cell count). Consider aortitis when signs and symptoms develop without known etiology. Discontinue UDENYCA® if aortitis is suspected. - Nuclear Imaging: Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. Consider when interpreting bone imaging results. ADVERSE REACTIONS: Most common adverse reactions (>= 5% difference in incidence compared to placebo) are bone pain and pain in extremity. To report SUSPECTED ADVERSE REACTIONS, contact 1-800-4-UDENYCA (1-800-483-3692) or notify the FDA at 1-800-FDA-1088 or UDENYCA® Prefilled Syringe: 6 mg/0.6 mL in a single-dose prefilled syringe for manual use only. UDENYCA® Autoinjector: 6 mg/0.6 mL in a single-dose prefilled autoinjector. UDENYCA ONBODY®: 6 mg/0.6 mL in a single-dose prefilled syringe co-packaged with the on-body injector for UDENYCA®. Advisors Smith, Anderson, Blount, Dorsett, Mitchell & Jernigan, L.L.P. acted as legal counsel to Accord and Intas with respect to the Transaction. About Intas Pharmaceuticals Intas Pharmaceuticals is a pioneer in biosimilars, having developed and launched one of the highest numbers of indigenous biosimilars in India. Intas Pharmaceuticals has a rich history of making quality biosimilars accessible to the masses in India. Intas' products like Neukine (filgrastim), Pegasta (Pegfilgrastim), Mabtas (rituximab), Razumab (ranibizumab) and Bevatas (bevacizumab) have transformed the management of their respective therapies in India. Eleftha is the latest testament to Intas' Biosimilar for Billions philosophy, fulfilling its commitment to provide quality care to the masses in India. Intas' biosimilars are manufactured at Intas Pharmaceuticals' European Union- Good Manufacturing Practices (EU-GMP) certified biotechnology plant located near Ahmedabad, Gujarat. For more information, visit About Accord BioPharma Accord BioPharma, Inc., the U.S. specialty division of Intas Pharmaceuticals, seeks to provide affordable, accessible, patient-centric therapies in oncology, immunology, and critical care. With a focus on improving the patient experience, Accord BioPharma goes beyond the biology of medicine to see disease from the patients' perspective and develop high-quality therapies that impact patients' lives. Accord BioPharma believes in the ability of biosimilars to increase access to a number of biologic medicines, that in the past may not have been considered for patients due to their high costs. Accord BioPharma looks forward to providing one of the deepest biosimilar portfolios in the industry. For more information, visit About Coherus BioSciences Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline that is expected to be synergistic with its proven commercial capabilities in oncology. References: 1. UDENYCA® Prescribing Information. Coherus BioSciences; December 2023. All trademarks, logos and brand names are the property of their respective owners. Logo:
Time of India
a day ago
- Time of India
Protein foods brand Gladful raises Rs 8 crore in fresh funding
Live Events Gladful, a clean-label food brand focused on nutrition for children, has raised Rs 8 crore in a funding round led by Eternal Capital by former BharatPe COO Dhruv Dhanraj Bahl . The round also saw participation from existing investors Antler India and Venture Catalysts, both of whom doubled down on their investment in the brand. Other participants include RWA Advisors, Arav Ventures, and angels Aman Tekriwal, and Sairam the brand raised Rs 7 crore—from Antler India, Venture Catalysts, and Shark Tank—in a seed round in brand's products, which are all centred around breakfast like chilla, dosa, pancake, and idli, provide 5–8 gms of protein per serve from largely plant-based sources. They are designed to prepare 10-minute meals—free from palm oil, refined sugar, maltodextrin, and other harmful additives. All of Gladful's products are manufactured in US FDA-registered facilities and tailored to the nutritional needs of growing Gladful also entered the Rs 12,000 crore kids' health drinks segment with NutraMilk — a clean-label alternative made with nuts, seeds, jaggery, dates, and 25 essential vitamins and minerals. The category expansion was driven by deep consumer insights, especially from mothers seeking a nutritious, sugar-free milk mix for daily Sharma, Co-founder & CEO of Gladful, said in a statement, 'We're here to redefine childhood nutrition and wellness in India. From breakfast to mid-morning snacks to lunchboxes, we're building a future where clean, protein-packed meals are the default, not the exception. We understand how tough parenting is today and are continuously working towards solutions that make parenting easy.'The company plans to use the fresh capital to strengthen its core team across R&D, marketing, and growth; invest in innovation; and deepen digital distribution—especially on quick-commerce Dhanraj Bahl, Founder & Managing Partner, Eternal Capital, said in a statement, 'Gladful is creating a 'trusted, protein-first' brand that parents have been searching for — an easy, guilt-free 'yes' in every kitchen. Today's parents are reading the fine print on health drinks and are rejecting the old guard of sugar and fillers. Gladful's offering, especially their Nutra milk mix, is the intelligent answer to that shift. We invested because with them, you're not just trusting a product, you're also trusting the founders, their commitment to the vision, and their stellar execution.'
